These results provide an innovative characterization of CXCL13 distribution and M2 infiltration across the astrocytoma subgroups, setting the basis for diagnostics and therapeutic insights that may contribute to the application of immunotherapies in human astrocytoma. Here, CXCL13 is linked to astrocytoma (excluding glioblastoma).